Rejuve Therapeutics is a biotechnology company pioneering the next generation of gene-driven rejuvenation therapies. Our work began with the belief: cellular rejuvenation and dedifferentiation—long believed to be inseparable during reprogramming—can in fact be decoupled.
By specifically inhibiting the dedifferentiation pathway during the reprogramming process on our proprietary rejuvenation screening platform, we successfully achieved the demonstration of gene-mediated rejuvenation that preserves native cell identity, successfully reversing aging in human arterial endothelial cells without triggering pluripotency or tumor-associated risks. Our long-term aim is to develop simplified, clinically actionable rejuvenation gene cocktails
Building upon this foundation, we are constructing the first Longitudinal Human Aging and Rejuvenation Gene Expression Atlas, enabling high-resolution mapping of the molecular events that drive aging and its reversal.
We are now actively collaborating with leading AI scientists to launch the next stage of our platform—leveraging advanced AI methodologies such as Dynamic Graph Modeling, as well as transfer learning to adapt state-of-the-art scRNA-seq foundation models for aging and rejuvenation. These efforts will enable AI-guided gene perturbation analysis and support our pursuit of simplified, clinically actionable rejuvenation gene cocktails..
Dr. Gordon Ma is a geneticist, stem cell biologist, and biotech founder with over 20 years of experience in epigenetics, gene regulation, and rejuvenation biology. His PhD work produced the first evidence of CDH1 promoter methylation in precancerous tissue—a foundational contribution to modern epigenetics. He completed postdoctoral training at Harvard Medical School and the University of Colorado, where he studied XIST-mediated epigenetic regulation.
At the NIH (NHLBI), Dr. Ma conducted research in embryonic stem cell differentiation and cardiovascular regenerative biology and made key findings on mitochondrial regulation of pluripotency. He later founded several life science companies while continuing NIH research as a special volunteer for nearly a decade.
As Founder and CEO of Rejuve Therapeutics, Dr. Ma is the principal inventor of a patented method demonstrating gene-driven rejuvenation without dedifferentiation. His ongoing work includes large-scale single-cell sequencing studies and the development of the first Longitudinal Human Aging and Rejuvenation Gene Expression Atlas. He is collaborating closely with AI scientists on transfer learning and biological foundation models to identify key regulatory genes driving aging and rejuvenation and to develop clinically viable rejuvenation gene cocktails
Dr. Aibing Wang is a distinguished biomedical scientist with over 23 years of experience in molecular biology, cell biology, oncology, and vaccine development. He earned his Ph.D. in Biochemistry and Molecular Biology from Peking Union Medical College and has made significant contributions in both academia and industry. As a former Research Assistant Professor at Georgetown University, Dr. Wang focused on cancer development and drug discovery, pioneering research on TERT’s role in tumorigenesis and screening novel therapeutics for cervical cancer. His expertise extends to developing lipid nanoparticle-based targeted therapies for brain tumors and conducting extensive in vivo studies. With 84 publications, five patents, and three NIH awards, his work has had a lasting impact on biomedical innovation. At Rejuve Therapeutics, with extensive experience in molecular biology, cell biology, oncology, and vaccine development, Dr. Wang focus on the development of packaging and delivery solutions of our new rejuvenation gene cocktails for in vitro and in vivo studies
Dr. Dazhi Lai is a highly accomplished scientist and entrepreneur with expertise in immunology, regenerative medicine, aging, biotechnology, and drug development. He earned his Ph.D. in Biotechnology from the Academy of Military Medical Sciences and completed postdoctoral training at Yale University. His research has spanned virology, immunology, aging, and therapeutic development, leading to significant discoveries, including calcium signaling in innate immunity and transcriptional regulation of immune responses. Dr. Lai has also spearheaded the development of innovative recombinant proteins and monoclonal antibodies for drug discovery. His leadership in translational research has resulted in multiple patents and FDA-approved therapeutics. Passionate about bridging scientific discovery with clinical application, he continues to push the boundaries of biomedical innovation. At Rejuve Therapeutics, Dr. Lai’s leadership and scientific expertise in immunology and regenerative medicine continue to drive innovation in the area of aging and rejuvenation in human immune system.
